VIR — Vir Biotechnology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1706431 ·
Last close
$8.66
Market Cap
$1.46B
52W High
$10.58
52W Low
$8.16
ADV30
2,084,633
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | -41,000 | — | -132,290,000 | -125,695,000 | 1,025,585,000 | 274,161,000 | 212,820,000 |
| Dec 2025 | 63,760,000 | 63,734,000 | -47,921,000 | -42,923,000 | 1,002,823,000 | 232,185,000 | 237,547,000 |
| Sep 2025 | -65,000 | -54,000 | -173,443,000 | -163,141,000 | 1,019,453,000 | 170,084,000 | 223,355,000 |
| Jun 2025 | 1,031,000 | 1,020,000 | -118,589,000 | -110,958,000 | 1,192,532,000 | 211,104,000 | 245,060,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-446,051,000
Investing CF
$195,388,000
Financing CF
$165,710,000
CapEx
$-3,593,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.13
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,323,466,000
Inventory
—
Receivables
—
ST Investments
$202,138,000
EBIT TTM
$-472,243,000
Pretax Income TTM
$-442,346,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$65,495,000
EBITDA
$-451,048,992
Free Cash Flow
$-214,927,632
Enterprise Value
$1,079,806,080
Total Cash
$476,299,008
Total Debt
$95,579,000
Shares Out
168,651,974
Trailing EPS
$-3.13
Book Value
$5.04
ROE
-47.7%
ROA
-24.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 66,520,000 | -479,510,000 | -437,987,000 | 1,002,823,000 | 237,547,000 | — | -391,781,000 |
| Dec 2024 | 63,712,000 | -552,170,000 | -521,960,000 | 1,398,813,000 | 248,428,000 | — | -446,352,000 |
| Dec 2023 | 39,494,000 | -670,746,000 | -615,061,000 | 1,919,060,000 | 328,824,000 | — | -778,785,000 |
| Dec 2022 | 1,580,472,000 | 833,068,000 | 515,837,000 | 2,802,088,000 | 724,125,000 | — | 1,663,253,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.32
Max Pain — expiry 2026-10-16
max pain strike: $9.00 · spot: $8.66 · call oi: 2,653 · put oi: 612
Expected Move to 2026-10-16:
±$3.85
(44.46%) —
implied range
$4.81 –
$12.51
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLBT | SL Science Holding Ltd | $1.48B | $2.64 | — |
| MAZE | Maze Therapeutics, Inc. | $1.49B | $26.92 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.40B | $16.52 | — |
| ALVO | Alvotech | $1.39B | $4.12 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.57B | $3.00 | — |
News headlines (Yahoo Finance, 1h cache)
Vir Biotechnology (VIR) Could Be 60% Undervalued On CFO Transition
2026-08-01 00:14 · Yahoo
Vir Biotechnology Announces Chief Financial Officer Transition
2026-07-24 12:30 · Yahoo
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
2026-07-22 20:05 · Yahoo
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
2026-07-03 00:00 · Yahoo
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
2026-06-26 11:00 · Yahoo
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
2026-06-07 20:14 · Yahoo
How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story
2026-05-24 14:13 · Yahoo
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
2026-05-23 22:33 · Yahoo
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
2026-05-18 15:19 · Yahoo
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
2026-05-17 20:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.